ESPE Abstracts

Dual hormone closed-loop insulin/glucagon delivery has been successfully used in in- and out-patient clinical setting with a reduction in hypoglycemia and improvement in time in range of glucose concentration. However, the main goal of the dual hormone closed-loop systems – complete prevention of hypoglycemia – has not been achieved. In the latest published studies with dual hormone closed-loop systems the amount of intervention with oral carbohydrates is still almos...

Background: The duodenal-jejunal bypass liner (DJBL) is an endoscopically placed and removable bariatric device associated with weight loss and metabolic improvements in adults.Objective and hypotheses: To determined efficacy and safety of DJBL up to 1 year in morbidly obese adolescents.Method: About 14 obese adolescents with prediabetes or type 2 diabetes (10 female, mean (SD) age 17.7 (1.1) years) underwent endoscopic placement o...

Background: The duodenal–jejunal bypass liner (DJBL) is an endoscopically placed and removable intestinal liner that creates a duodenal–jejunal bypass. Weight loss and diabetes improvement was reported in the adults.Objective and hypotheses: To evaluate clinical effects and safety of this device in severely obese adolescents with obesity complications.Method: Six morbidly obese adolescents (four female, mean age 18.2 year...

Background: GH administration restores normal growth in children with GH deficiency (GHD). However, current daily s.c. injection treatment regimens may be inconvenient leading to impaired adherence and subsequently suboptimal treatment outcomes. NNC0195-0092 is a novel, reversible albumin-binding GH developed for once-weekly administration.Objective and hypotheses: This was a randomised, open-label, active-controlled, dose-escalation trial (NCT01973244) ...

Background: Growth hormone deficiency (GHD) requires long-term daily injections with GH replacement therapy and is associated with considerable treatment burden by patients and caregivers. Somapacitan is a long-acting GH derivative that is being developed for once-weekly dosing in adults and children with GHD. A well-established protraction method, which is successfully in use to extend the half-life of insulin and glucagon-like peptide (GLP)-1, has been applied in developing ...

Background: Gonadotropin-releasing hormone (GNRH) and its receptor (GNRHR) are central regulators of puberty. Loss-of-function mutations of the GNRH-GNRHR signaling pathway are associated with congenital hypogonadotropic hypogonadism, but no mutations were reported so far in patients with central precocious puberty (CPP). Animal data demonstrate the importance of microRNAs in pubertal timing regulation. Among others, miR200b regulates Gnrh1 gene expression in GnRH neu...

Objectives: PATRO Children is a non-interventional, international, longitudinal study of the long-term safety of a recombinant human growth hormone (rhGH; Omnitrope®, Sandoz). In particular, the study will assess the diabetogenic potential of rhGH and the risk of malignancies. The long-term efficacy is a secondary objective of the study.Methods: The study population includes infants, children and adolescents receiving Omnitrope®...

Objective: International Societies for diabetes care are aiming to facilitate and improve the uptake of diabetes technologies. This survey investigated healthcare professional (HCP) evaluation of the role of technology in diabetes care within their centres.Methods: Between April to November 2017, 215 HCPs from six continents (132 Europe, 36 Asia, 23 North and 7 South America, 9 Africa and 8 Australasia) replied to an online survey and provided data for a...

Background: Congenital hypogonadotropic hypogonadism (HH) is a rare but clinically and genetically heterogeneous disease characterized by an absent or incomplete puberty and infertility. The association of HH with hyposmia or anosmia is defined as Kallmann syndrome. Molecular genetic testing of HH is valuable, as it can prompt the treatment in adolescence.Objective and hypotheses: To identify causative variants in genes associated with HH in a cohort of ...

Background: Resistance to thyroid hormones (RTH) is a rare disease, characterized by reduced sensitivity of target tissues to thyroid hormones. Pathognomonically, thyroid hormones are moderately elevated, whereas TSH levels are inappropriately normal or elevated. Over 100 thyroid hormone receptor beta (THRB) mutations have been reported, which are found in around 85% of RTH cases. Hypercholesterolemia was not previously reported in RTH patients....